trending Market Intelligence /marketintelligence/en/news-insights/trending/CBVHI06j6qbxVUEPuxWVOg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Progenics' imaging agent shows promise in localizing cancer in late-stage study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Progenics' imaging agent shows promise in localizing cancer in late-stage study

Progenics Pharmaceuticals Inc. said its imaging agent PyL helped in localizing tumors in prostate cancer patients with biological recurrence of the disease in a late-stage study.

Localization of cancer is the process of determining the location of the disease or keeping the disease in a specific location. Biological recurrence is when the disease comes back after treatment with surgery or radiation, even when patients do not suffer from symptoms.

The New York-based biotechnology company said that PyL, or 18F-DCFPyL, achieved the main goal of the study, dubbed Condor, with a correct localization rate of 84.8% to 87% in the 208 patients enrolled in the trial by using three blinded independent readers. The agents helped in localizing at least one lesion.

In addition, the company said PyL was well-tolerated in patients, consistent with the phase 2 Osprey study results. However, one patient suffered from hypersensitivity while four patients experienced headaches.

Progenics said it plans to file an application with the U.S. Food and Drug Administration in the second half of 2020 for the approval of the agent. Detailed results of the study will be presented at an upcoming medical meeting.

According to the company's Dec. 23 press release, prostate cancer is the second-most common form of cancer affecting men in the U.S. The American Cancer Society estimates that each year approximately 174,650 new cases of prostate cancer will be diagnosed and about 31,620 men will die of the disease.